Disease Domain | Count |
---|---|
Neoplasms | 1 |
Infectious Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 2 |
Mechanism A1R agonists [+6] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. KR |
First Approval Date26 Aug 2024 |
Target |
Mechanism NTRK inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism IDO1 inhibitors [+1] |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date21 Sep 2020 |
Sponsor / Collaborator Chabiotech Co., Ltd. [+1] |
Start Date07 Oct 2019 |
Sponsor / Collaborator |
Start Date09 Aug 2019 |
Sponsor / Collaborator Handok, Inc. [+1] |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Acetaminophen/Chlorpheniramine Maleate/Pseudoephedrine Hydrochloride/Guaifenesin/Caffeine ( A1R x A2aR x Adenosine receptor x COX x H1 receptor x PDE x α-adrenergic receptor ) | Common Cold More | Approved |
HL-5101 ( NTRK ) | Neoplasms More | Phase 1 |
CMG-017 ( IDO1 x TDO ) | Neoplasms More | Pending |